Patents by Inventor Emma Atkinson

Emma Atkinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGF-?3 mutants
    Patent number: 7947264
    Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilizing substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: May 24, 2011
    Assignee: Renovo Limited
    Inventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
  • TGF-BETA3 MUTANTS
    Publication number: 20110105396
    Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 5, 2011
    Applicant: Renovo Limited
    Inventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
  • Medicaments and proteins based on TGF-? monomers for the treatment of wounds
    Patent number: 7902150
    Abstract: There is provided the use of monomeric TGF-?s, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-?3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: March 8, 2011
    Assignee: Renovo Limited
    Inventors: Mark William James Ferguson, Phillip Mellors, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
  • MEDICAMENTS AND PROTEINS BASED ON TGF-BETA MONOMERS FOR THE TREATMENT OF WOUNDS
    Publication number: 20090137475
    Abstract: There is provided the use of monomeric TGF-?s, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-?3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.
    Type: Application
    Filed: March 12, 2007
    Publication date: May 28, 2009
    Inventors: Mark William James Ferguson, Phillip Mellor, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson
  • PROTEINS, NUCLEIC ACIDS AND MEDICAMENTS
    Publication number: 20090105146
    Abstract: The invention provides TGF-?3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-?3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-?3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-?3 is replaced with Proline. Further still, the invention provides TGF-?3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-?3 and/or the Arginine residue at position (52) of full-length wild type TGF-?3. The invention also provides medicaments and methods of treatment using such TGF-?3s.
    Type: Application
    Filed: March 12, 2007
    Publication date: April 23, 2009
    Applicant: RENOVO LIMITED
    Inventors: Mark William James Ferguson, Phillip Mellor, Hugh Gerard Laverty, Nick Occleston, Sharon O'Kane, Emma Atkinson